| Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal … GW Scadding, MA Calderon, MH Shamji, AO Eifan, M Penagos, F Dumitru, ... JAMA: Journal of the American Medical Association 317 (6), 615-625, 2017 | 217 | 2017 |
| Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study SM Jones, EH Kim, KC Nadeau, A Nowak-Wegrzyn, RA Wood, ... The Lancet 399 (10322), 359-371, 2022 | 150 | 2022 |
| Highly variable population-based prevalence rates of unilateral hearing loss after the application of common case definitions DS Ross, SN Visser, WJ Holstrum, T Qin, A Kenneson Ear and hearing 31 (1), 126-133, 2010 | 104 | 2010 |
| Synchronous immune alterations mirror clinical response during allergen immunotherapy A Renand, MH Shamji, KM Harris, T Qin, E Wambre, GW Scadding, ... Journal of Allergy and Clinical Immunology 141 (5), 1750-1760. e1, 2018 | 66 | 2018 |
| Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy MH Shamji, D Larson, A Eifan, GW Scadding, T Qin, K Lawson, ML Sever, ... Journal of Allergy and Clinical Immunology 148 (4), 1061-1071. e11, 2021 | 60 | 2021 |
| Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance EB Simon Glatigny, Barbara Höllbacher, Samantha J. Motley, Cathy Tan ... The Journal of Immunology 202 (5), 1373-1382, 2019 | 51 | 2019 |
| Nasal allergen challenge and environmental exposure chamber challenge: a randomized trial comparing clinical and biological responses to cat allergen D Larson, P Patel, AM Salapatek, P Couroux, D Whitehouse, A Pina, ... Journal of Allergy and Clinical Immunology 145 (6), 1585-1597, 2020 | 29 | 2020 |
| Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial J Corren, D Larson, MC Altman, RM Segnitz, PC Avila, PA Greenberger, ... Journal of Allergy and Clinical Immunology 151 (1), 192-201, 2023 | 27 | 2023 |
| Delta activity independent of its activity as a ligand of Notch LP Mok, T Qin, B Bardot, M LeComte, A Homayouni, F Ahimou, C Wesley BMC Developmental Biology 5, 1-12, 2005 | 20 | 2005 |
| Immune Tolerance Network. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised … SM Jones, EH Kim, KC Nadeau, A Nowak-Wegrzyn, RA Wood, ... Lancet 399 (10322), 359, 2022 | 17 | 2022 |
| Peanut-specific IgG4 and IgA in saliva are modulated by peanut oral immunotherapy JM Smeekens, C Baloh, N Lim, D Larson, T Qin, L Wheatley, EH Kim, ... The Journal of Allergy and Clinical Immunology: In Practice 10 (12), 3270-3275, 2022 | 10 | 2022 |
| Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy J Calise, H DeBerg, N Garabatos, S Khosa, V Bajzik, LB Calderon, ... Journal of Allergy and Clinical Immunology 152 (1), 155-166. e9, 2023 | 6 | 2023 |
| Effects of combined treatment with cat allergen immunotherapy and tezepelumab on nasal allergen challenge J Corren, L Wheatley, S Sanda, D Larson, T Qin, P Avila, F Baroody, ... Journal of Allergy and Clinical Immunology 145 (2), AB336, 2020 | 6 | 2020 |
| Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study … SM Jones, EH Kim, KC Nadeau, A Nowak-Wegrzyn, RA Wood, ... DOI: https://doi. org/10.1016/S0140-6736 (21), 02390-4, 0 | 6 | |
| Tolerance development following oral immunotherapy (OIT) in 1-3 year old children with peanut allergy: findings from the Immune Tolerance Network (ITN) IMPACT trial S Jones, E Kim, K Nadeau, A Nowak-Wegrzyn, R Wood, H Sampson, ... Journal of Allergy and Clinical Immunology 145 (2), AB338, 2020 | 4 | 2020 |
| Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy MC Altman, RM Segnitz, D Larson, ND Jayavelu, MT Smith, S Patel, ... Journal of Allergy and Clinical Immunology 152 (5), 1247-1260, 2023 | 2 | 2023 |
| Peanut-Specific IgA and IgG4 in Saliva are Modulated by Peanut OIT M Kulis, J Smeekens, D Larson, T Qin, AW Burks Journal of Allergy and Clinical Immunology 145 (2), AB181, 2020 | 2 | 2020 |
| Efficacy and Safety of Oral Immunotherapy in a Randomized, Placebo-Controlled Study of 1–3-Year Old Children with Peanut Allergy: Findings from the Immune Tolerance Network … ITN050AD IMPACT Study Team Lancet (London, England) 399 (10322), 359, 2022 | 1 | 2022 |
| Relationship between response to grass pollen nasal allergen challenge and seasonal symptoms and the effect of treatment compliance A Eifan, G Scadding, M Calderon, M Shamji, M Penagos, P Alder-Wurtzen, ... CLINICAL AND EXPERIMENTAL ALLERGY 47 (12), 1686-1687, 2017 | | 2017 |
| Response to Nasal Challenge Correlates with Seasonal Outcomes during Grass Pollen Immunotherapy with Either Subcutaneous or Sublingual Immunotherapy G Scadding, AO Eifan, MA Calderon, MH Shamji, M Penagos, PA Wurtzen, ... Journal of Allergy and Clinical Immunology 139 (2), AB385, 2017 | | 2017 |
